Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2016

Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2016


  • Products Id :- GDHC3697CTIDB
  • |
  • Pages: 595
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, ''Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2016'' provides an overview of Graft Versus Host Disease (GVHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials 29

Prominent Drugs 31

Latest Clinical Trials News on Graft Versus Host Disease (GVHD) 32

Jun 21, 2016: Cynata Prepares for Phase 1 Clinical Trial 32

Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 32

Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers 33

Clinical Trial Profile Snapshots 34

Appendix 593

Abbreviations 593

Definitions 593

Research Methodology 594

Secondary Research 594

About GlobalData 595

Contact Us 595

Disclaimer 595

Source 596

List of Figures

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14

Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2016* 15

Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17

Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18

Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2016* 19

Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20

Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

GlobalData Methodology 594

List of Tables

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14

Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2016* 15

Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17

Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18

Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2016* 19

Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20

Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase, 2016* 22

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23

Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30

Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd.

Novartis AG

Sanofi

Pfizer Inc.

Mallinckrodt Plc

Neopharm Ltd.

Kiadis Pharma N.V.

Celgene Corporation

Bellicum Pharmaceuticals, Inc.

Amgen Inc.

Graft Versus Host Disease (GVHD) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Graft Versus Host Disease (GVHD), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

select a license

Single User License
USD 2500 INR 161200
Site License
USD 5000 INR 322400
Corporate User License
USD 7500 INR 483600

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com